Kilitch Drugs (India) (NSE:KILITCH) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹185.31
GF Value ₹232.78
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Research & Development?

Kilitch Drugs (India) NSE:KILITCH -2.89% 84 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹232.78 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kilitch Drugs (India)'s Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Kilitch Drugs (India)  (NSE:KILITCH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kilitch Drugs (India) Research & Development Related Terms

Kilitch Drugs (India) Research & Development Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Research & Development Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Research & Development too high?
Kilitch Drugs (India)'s current Research & Development is ₹0 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Research & Development compare to ZTS?
Kilitch Drugs (India)'s Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹232.78, compared to a current price of ₹185.31 — trading 20.4% below its estimated fair value. The current Research & Development is ₹0 Mil. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹185.31 is trading 20.4% below its estimated GF Value™ of ₹232.78. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹232.78 vs. price of ₹185.31 (20.4% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹185.31
Price
₹232.78
GF Value